Wall Street brokerages expect Castle Biosciences (NASDAQ:CSTL) to announce sales of $10.28 million for the current quarter, according to Zacks. Two analysts have made estimates for Castle Biosciences’ earnings. The highest sales estimate is $10.32 million and the lowest is $10.23 million. The firm is expected to issue its next earnings report on Tuesday, December 3rd.
According to Zacks, analysts expect that Castle Biosciences will report full year sales of $40.54 million for the current financial year, with estimates ranging from $40.31 million to $40.77 million. For the next year, analysts expect that the business will report sales of $49.93 million, with estimates ranging from $48.13 million to $51.73 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Castle Biosciences.
Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Tuesday, September 3rd. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.51) by ($0.54). The company had revenue of $10.74 million during the quarter, compared to analyst estimates of $7.06 million.
Several brokerages have recently weighed in on CSTL. Leerink Swann set a $33.00 price target on Castle Biosciences and gave the company a “buy” rating in a research report on Wednesday, September 4th. Svb Leerink began coverage on Castle Biosciences in a research report on Monday, August 19th. They set an “outperform” rating and a $28.00 price target on the stock. Robert W. Baird upped their price target on Castle Biosciences from $27.00 to $31.00 and gave the company an “outperform” rating in a research report on Wednesday, September 4th. Canaccord Genuity upped their price target on Castle Biosciences from $26.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Finally, BTIG Research upped their price target on Castle Biosciences to $32.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Five equities research analysts have rated the stock with a buy rating, Castle Biosciences has an average rating of “Buy” and an average target price of $31.60.
In other Castle Biosciences news, major shareholder Mgc Venture Partners 2013 Gp, acquired 312,500 shares of the business’s stock in a transaction dated Monday, July 29th. The stock was bought at an average price of $16.00 per share, with a total value of $5,000,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director David S. Kabakoff acquired 62,500 shares of the business’s stock in a transaction dated Monday, July 29th. The shares were acquired at an average cost of $16.00 per share, with a total value of $1,000,000.00. The disclosure for this purchase can be found here.
Shares of CSTL traded up $0.06 during midday trading on Wednesday, hitting $23.00. 229,699 shares of the company traded hands, compared to its average volume of 130,979. The stock’s 50-day moving average is $22.79. Castle Biosciences has a one year low of $17.11 and a one year high of $28.50.
Castle Biosciences Company Profile
Castle Biosciences, Inc, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue.
Featured Article: How does a dividend reinvestment plan work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.